Abstract: SA-PO0822
Real-World Use of SGLT2 Inhibitors for Patients with IgAN and Glomerulonephritis, 2021-2023
Session Information
- Glomerular Management: Real-World Lessons and Emerging Therapies
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Huang, Yunru Claire, Genentech Inc, South San Francisco, California, United States
- Boppudi Naga, Sai Sriteja, Genesis Research, Hoboken, New Jersey, United States
- Lindsay, Lisa, Genentech Inc, South San Francisco, California, United States
- Kamath, Nikhil, Roche Inc, Welwyn Garden City, United Kingdom
- Cheng, Ji (Emmy), Roche Inc, Mississauga, Ontario, Canada
- Duggal, Vishal, Genentech Inc, South San Francisco, California, United States
Background
The increasing use of SGLT2 inhibitors (SGLT2i) among patients (pts) with kidney diseases may affect clinical trial design and interpretability for glomerulonephritis (GN) conditions such as IgA nephropathy (IgAN).
Methods
This retrospective cohort study characterized SGLT2i use in adult pts with GN, including IgAN, using US-based insurance claims (IQVIA Pharmetrics Plus). Pts were included who: were diagnosed with GN via ICD codes from October 1, 2015, to June 30, 2023, had a kidney biopsy on or prior to diagnosis, and did not use SGLT2i before 2021. SGLT2i use was separately assessed between 2021 and 2023 for GN pts diagnosed before and after 2021.
Results
The study included 2703 GN pts (338 IgAN) diagnosed pre-2021 and 2923 pts (354 IgAN) diagnosed post-2021. SGLT2i use was 11.2% in GN and 14.5% in IgAN pts diagnosed pre-2021, and 18.4% in GN and 26% in IgAN pts diagnosed post-2021. SGLT2i use increased from 2021 to 2023 (Fig. 1). Median time to SGLT2i initiation was 4 months in GN and 3 months in IgAN pts diagnosed post-2021. Factors associated with SGLT2i use among GN pts were: male, commercial insurance, and co-existing hypertension and/or diabetes (DM). SGLT2i use was more common among IgAN pts with DM (Fig. 2).
Conclusion
SGLT2i use increased, but remained relatively low in pts with GN and IgAN between 2021 and 2023. Current GN/IgAN clinical trials may better reflect real-world use of SGLT2i, which should be considered in trial interpretation and comparison.